KEI Comments in response to the Office of Science and Technology Policy (OSTP) Request for Information (RFI), regarding National Priorities for Artificial Intelligence

Robot working on laptop

KEI Comments in response to the Office of Science and Technology Policy (OSTP) Request for Information (RFI), regarding National Priorities for Artificial Intelligence, as noticed on May 23, 2023 in the Federal Register, 88 FR 34194. July 7, 2023 Knowledge… Continue Reading

KEI response to NTIA request for comments on AI Accountability Policy, expressing concerns over trade agreement provisions which limit the transparency of source code and algorithms

KEI-NTIA-AI-Accountability-RFC KEI response to NTIA request for comments on AI Accountability Policy, expressing concerns over trade agreement provisions which limit the transparency of source code and algorithms RE: Notice by the National Telecommunications and Information Administration on 04/13/2023, Document Citation:… Continue Reading

KEI Testimony regarding the opportunities to use differential USPTO fees to achieve additional social objectives

KEI-USPTO-fees18may2023 Testimony of James Love Representing Knowledge Ecology International (KEI) regarding the opportunities to use differential USPTO fees to achieve additional social objectives USPTO Patent Public Advisory Committee Public Hearing on the Proposed Patent Fee Schedule May 18, 2023 Introduction… Continue Reading

Cancer patients file administrative appeal on NIH rejection of Xtandi march-in petition with Secretary of HHS Becerra

On March 23, 2023, three prostate cancer patients, Robert Sachs, Clare Love and Eric Sawyer, filed an administrative appeal of the NIH decision to reject petition that HHS use Federal rights in patents on Xtandi to address pricing discrimination against… Continue Reading

US government files statement of Interest in Arbutus v Moderna case, testing scope of 28 USC 1498(a) government use of patents for acquisition and distribution of COVID 19 vaccines

On February 14, 2023, USDOJ filed a Statement of Interest of the United States, in the patent dispute between Arbutus Biopharma, Genevant Sciences, and Moderna. A copy of the filing is here: arbutus.moderna.USG.statementofinterest This is an important, and while not… Continue Reading